Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II cabazitaxel as second-line treatment in HER2-negative metastatic breast cancer
2011-003625-97Phase 2Completed
- Sponsor
- HeCOG
- Start
- Aug 2012
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in breast cancer, sponsored by HeCOG. Primary endpoint: Objective response rate. Started Aug 2012; status: completed.
02
Drugs
cabazitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-003625-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003625-97.